---
schema_version: "secwatch.filing_event.v1"
accession: "0001753926-24-001236"
form_type: "8-K"
ticker: "VANI"
cik: "0001266806"
company_name: "Vivani Medical, Inc."
filed_at: "2024-07-11T23:59:59+00:00"
generated_at: "2026-05-31T21:42:15.131749+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Vivani to start LIBERATE-1 study of GLP-1 implant for obesity in Q4 2024

## Summary
- NPM-115 is a 6-month exenatide implant for chronic weight management in obese/overweight patients.
- LIBERATE-1: 24 patients randomized to implant, Bydureon BCise, or semaglutide for 9 weeks.
- Study expected to begin Q4 2024 in Australia; data projected in 2025.
- FDA cleared IND for NPM-119 (type 2 diabetes) in June 2024; company prioritized NPM-115.
- Company plans to use Australian R&D incentives to defray trial costs.

## SEC filing metadata
- accession: 0001753926-24-001236
- form_type: 8-K
- ticker: VANI
- cik: 0001266806
- company_name: Vivani Medical, Inc.
- filed_at: 2024-07-11T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1266806/000175392624001236/0001753926-24-001236-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1266806/000175392624001236/g084331_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001753926-24-001236
- JSON: https://secwatch.observer/filing/0001753926-24-001236.json
- Plain text: https://secwatch.observer/filing/0001753926-24-001236.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.